Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or quantified.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours.

British journal of cancer·2015
Same author

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.

Leukemia·2012
Same author

Basic principles for the study of metastasis using animal models.

Methods in molecular medicine·2011
Same author

Isolated groin recurrence in vulval squamous cell cancer (VSCC). The importance of node count.

European journal of gynaecological oncology·2010
Same author

Guidelines for the welfare and use of animals in cancer research.

British journal of cancer·2010
Same author

Cross-platform Q-TOF validation of global exo-metabolomic analysis: application to human glioblastoma cells treated with the standard PI 3-Kinase inhibitor LY294002.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2008

Related Experiment Video

Updated: Jun 21, 2026

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

Technology evaluation: CEA-Scan, Immunomedics Inc.

S A Eccles1

  • 1McElwain Labs, 15 Cotswold Road, Sutton, Surrey, UK. suzan@icr.ac.uk

Current Opinion in Molecular Therapeutics
|July 25, 2009
PubMed
Summary
This summary is machine-generated.

Radioimmunoscintigraphy (RIS) using CEA-Scan, a radiolabeled antibody fragment, aids in detecting colorectal and breast cancer recurrence. This imaging technique can alter treatment decisions by identifying disease missed by other methods.

More Related Videos

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Related Experiment Videos

Last Updated: Jun 21, 2026

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Immunology

Background:

  • Radioimmunoscintigraphy (RIS) uses radiolabeled monoclonal antibodies (mAbs) for cancer imaging.
  • Efficacy depends on antigen expression, antibody properties, and imaging techniques.

Purpose of the Study:

  • To evaluate the utility of CEA-Scan (99mTc-labeled Fab' fragment against CEA) in cancer imaging.
  • To assess its role in detecting recurrent or metastatic disease in colorectal and breast cancer.

Main Methods:

  • Utilized CEA-Scan for Single Photon Emission Computed Tomography (SPECT) imaging.
  • Compared CEA-Scan performance with CT and mammography.
  • Investigated intra-operative radio-immunoguided surgery applications.

Main Results:

  • CEA-Scan is approved for colorectal cancer SPECT imaging in North America and Europe.
  • It complements CT in detecting recurrent/metastatic disease, including liver metastases.
  • Provides clearer identification of breast cancer than mammography and is used in radio-immunoguided surgery.

Conclusions:

  • CEA-Scan provides clinically useful information that can alter treatment decisions.
  • Benefits include reducing unnecessary procedures in inoperable patients.
  • Potential for greater benefit in colorectal cancer if therapies for minimal residual disease emerge.